Company profile
Hepion Pharmaceuticals, Inc.
OTC: HEPA · Healthcare · Biotechnology
PublicHQ Edison, NJCIK 0001583771Reports USD
#1161 of 1,418 Healthcare companies by revenue
EA Score
24DFH 26DQ 19GM —SS 30
v0.1 · 55/100 weight · provisional
↑ balance-sheet leverage, listing tenure · ↓ Piotroski F, workforce scale
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$8.3M
Employees
2
as of 2026-08-26
Market cap
$614.2k
as of 2026-08-26
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02023
Net income-$8.3M-$8.3M2025
Operating income-$4.2M-$4.2M2025
Total assets$3.1M$3.1M2025
Liabilities$402.4k$402.4k2025
Equity$2.7M$2.7M2025
Revenue trend
FY2021 – FY2023 · USD
FY21
FY21
FY22
FY23
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Hepion Pharmaceuticals, Inc.’s revenue?
Hepion Pharmaceuticals, Inc. booked $0 in FY2023 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Innovation Pharmaceuticals Inc.——NKGen Biotech, Inc.——ChitogenX Inc.——4Cable TV International, Inc.——Apptly Health Technologies Corp.——Pond Technologies Holdings Inc.21DKey facts
CEOGary S. Stetz
SectorHealthcare
IndustryBiotechnology
HeadquartersEdison, NJ
ExchangeOTC: HEPA
Employees2
IPO date2014-02-10
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.